ASCAT 2023 | Emerging drug targets for sickle cell disease
In this interview, David Rees, FRCP, FRCPath, FRCPCH, King’s College London, London, UK, comments on emerging drug targets in sickle cell disease (SCD), a disease in which a plethora of abnormalities are exhibited and may present opportunities for drug development. The key primary process which is targeted by current therapies is hemoglobin polymerization, although the importance of processes such as inflammation, oxidative stress, and red cell dehydration is becoming increasingly more apparent. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
